Walder Wyss acted as legal counsel to Alentis Therapeutics on the USD 67 million series B financing round. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors Biomed Partners, BB Pureos
Tags :Markus R. Frick
VISCHER is advising Noema Pharma in this transaction. The team is led by Matthias Staehelin (Corporate, pictured left). Walder Wyss advised Gilde Healthcare Partners, Polaris Partners, Invus Capital and BioMedInvest as investors. The team included
The team was led by partner Alexander Gutmans (Transaction/M&A & Venture Capital - pictured) and partner Robert von Rosen (Transaction/M&A & Venture Capital)